CBD continues to inspire. The potential for the legal (medical) marijuana market and for further medical research is the future, CBD is set to be ‘the new medicine’. With more pharmaceutical companies entering the CBD market, the necessary medical research and clinical trials will result in even more high-quality evidence.
Already, The World Health Organization states that CBD shows no abuse or dependence potential and that “there is no evidence of public health related problems associated with the use of pure CBD”. Today, CBD is used to treat symptoms of anxiety, insomnia, and many types of chronic pain as well as specific conditions, notably:
In the UK and the rest of the world, there are 39 different conditions that have been evidenced as being either helped or cured by the use of medicinal cannabis and clearly, as more research is conducted, this list will grow. Already, those at the sharp end - living with constant pain, debilitating or terminal illnesses - are fundraising, lobbying and raising awareness of the issues around and need for consistent, affordable and reliable supply for what they may have been fortunate to have been prescribed.
The future will see Medicaleaf involved in this medical Research and Development, participating in the influencing and development of future legislation and regulation in the UK and in the emerging technology. The development of our innovative app designed to gather individual’s data, medical history and evidential tests to make and review a parametric prescription compared against meta data that any medical specialist can safely rely for prescribing is already underway, working with NIHR/NHS to demonstrate concept and efficacy.
A comprehensive guide to CBD published by Forbes illustrates the growing number of CBD products and the rise in popularity following recent research. “All of a sudden CBD products started showing up everywhere, with oils and gummies becoming the most popular products early on.” With the caveat that “Not all CBD products work the same”.